Cargando…
Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes
AIMS/INTRODUCTION: Recently, patient‐tailored statin therapy was proven effective for achieving target low‐density lipoprotein (LDL) cholesterol levels. It is unclear, however, whether this therapeutic modality would be effective for atherogenic lipid profiles and inflammation in patients with type ...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley-Blackwell
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025110/ https://www.ncbi.nlm.nih.gov/pubmed/24843697 http://dx.doi.org/10.1111/jdi.12074 |
_version_ | 1782316727210606592 |
---|---|
author | Son, Jang Won Kim, Dong Jun Lee, Chang Beom Oh, Seungjoon Song, Kee‐Ho Jung, Chan Hee Mok, Ji Oh Kim, Jong Hwa Moon, Min Kyong Choi, Kyung Mook Cho, Jae Hyoung Choi, Sung Hee Kim, Soo Kyung Park, Kang Seo Kim, Hye Soon Kim, In Joo Kim, Young Il Kim, Hae Jin Kim, Sang Yong Kim, Sungrae |
author_facet | Son, Jang Won Kim, Dong Jun Lee, Chang Beom Oh, Seungjoon Song, Kee‐Ho Jung, Chan Hee Mok, Ji Oh Kim, Jong Hwa Moon, Min Kyong Choi, Kyung Mook Cho, Jae Hyoung Choi, Sung Hee Kim, Soo Kyung Park, Kang Seo Kim, Hye Soon Kim, In Joo Kim, Young Il Kim, Hae Jin Kim, Sang Yong Kim, Sungrae |
author_sort | Son, Jang Won |
collection | PubMed |
description | AIMS/INTRODUCTION: Recently, patient‐tailored statin therapy was proven effective for achieving target low‐density lipoprotein (LDL) cholesterol levels. It is unclear, however, whether this therapeutic modality would be effective for atherogenic lipid profiles and inflammation in patients with type 2 diabetes. MATERIALS AND METHODS: The present study was an 8‐week, multicenter, single‐step titration trial of patient‐tailored atorvastatin therapy (10, 20 and 40 mg) according to baseline LDL cholesterol levels in 440 patients with type 2 diabetes. We measured the LDL particle size by polyacrylamide gel electrophoresis, and used high‐sensitivity C‐reactive protein (hsCRP) and adiponectin as surrogate markers of inflammation. RESULTS: In the intention‐to‐treat analysis, 91% of the patients achieved their LDL cholesterol targets (<2.6 mmol/L) at week 8. There were significant reductions at week 8 in total cholesterol, triglycerides, non‐high‐density lipoprotein cholesterol (HDL) cholesterol, and the total cholesterol:HDL cholesterol ratio compared with the baseline values for all of the doses. The mean LDL particle size was significantly increased, and the small, dense LDL cholesterol levels were decreased in a dose‐dependent manner over the study period. In addition, the hsCRP levels were decreased in those high‐risk patients with baseline hsCRP levels over 3 mg/L (P < 0.001), and the adiponectin levels tended to increase with all of the doses (P = 0.004) at 8 weeks. CONCLUSIONS: Patient‐tailored atorvastatin therapy based on LDL cholesterol at baseline was effective in ameliorating atherogenic LDL particle size and inflammation, in addition to achieving the target LDL cholesterol level without an undesirable effect on glycemic control in patients with type 2 diabetes. This trial was registered with ClinicalTrials.gov (no. NCT01239849). |
format | Online Article Text |
id | pubmed-4025110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Wiley-Blackwell |
record_format | MEDLINE/PubMed |
spelling | pubmed-40251102014-05-19 Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes Son, Jang Won Kim, Dong Jun Lee, Chang Beom Oh, Seungjoon Song, Kee‐Ho Jung, Chan Hee Mok, Ji Oh Kim, Jong Hwa Moon, Min Kyong Choi, Kyung Mook Cho, Jae Hyoung Choi, Sung Hee Kim, Soo Kyung Park, Kang Seo Kim, Hye Soon Kim, In Joo Kim, Young Il Kim, Hae Jin Kim, Sang Yong Kim, Sungrae J Diabetes Investig Articles AIMS/INTRODUCTION: Recently, patient‐tailored statin therapy was proven effective for achieving target low‐density lipoprotein (LDL) cholesterol levels. It is unclear, however, whether this therapeutic modality would be effective for atherogenic lipid profiles and inflammation in patients with type 2 diabetes. MATERIALS AND METHODS: The present study was an 8‐week, multicenter, single‐step titration trial of patient‐tailored atorvastatin therapy (10, 20 and 40 mg) according to baseline LDL cholesterol levels in 440 patients with type 2 diabetes. We measured the LDL particle size by polyacrylamide gel electrophoresis, and used high‐sensitivity C‐reactive protein (hsCRP) and adiponectin as surrogate markers of inflammation. RESULTS: In the intention‐to‐treat analysis, 91% of the patients achieved their LDL cholesterol targets (<2.6 mmol/L) at week 8. There were significant reductions at week 8 in total cholesterol, triglycerides, non‐high‐density lipoprotein cholesterol (HDL) cholesterol, and the total cholesterol:HDL cholesterol ratio compared with the baseline values for all of the doses. The mean LDL particle size was significantly increased, and the small, dense LDL cholesterol levels were decreased in a dose‐dependent manner over the study period. In addition, the hsCRP levels were decreased in those high‐risk patients with baseline hsCRP levels over 3 mg/L (P < 0.001), and the adiponectin levels tended to increase with all of the doses (P = 0.004) at 8 weeks. CONCLUSIONS: Patient‐tailored atorvastatin therapy based on LDL cholesterol at baseline was effective in ameliorating atherogenic LDL particle size and inflammation, in addition to achieving the target LDL cholesterol level without an undesirable effect on glycemic control in patients with type 2 diabetes. This trial was registered with ClinicalTrials.gov (no. NCT01239849). Wiley-Blackwell 2013-09-13 2013-03-26 /pmc/articles/PMC4025110/ /pubmed/24843697 http://dx.doi.org/10.1111/jdi.12074 Text en Copyright © 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd |
spellingShingle | Articles Son, Jang Won Kim, Dong Jun Lee, Chang Beom Oh, Seungjoon Song, Kee‐Ho Jung, Chan Hee Mok, Ji Oh Kim, Jong Hwa Moon, Min Kyong Choi, Kyung Mook Cho, Jae Hyoung Choi, Sung Hee Kim, Soo Kyung Park, Kang Seo Kim, Hye Soon Kim, In Joo Kim, Young Il Kim, Hae Jin Kim, Sang Yong Kim, Sungrae Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes |
title | Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes |
title_full | Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes |
title_fullStr | Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes |
title_full_unstemmed | Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes |
title_short | Effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes |
title_sort | effects of patient‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with type 2 diabetes |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025110/ https://www.ncbi.nlm.nih.gov/pubmed/24843697 http://dx.doi.org/10.1111/jdi.12074 |
work_keys_str_mv | AT sonjangwon effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT kimdongjun effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT leechangbeom effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT ohseungjoon effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT songkeeho effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT jungchanhee effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT mokjioh effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT kimjonghwa effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT moonminkyong effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT choikyungmook effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT chojaehyoung effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT choisunghee effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT kimsookyung effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT parkkangseo effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT kimhyesoon effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT kiminjoo effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT kimyoungil effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT kimhaejin effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT kimsangyong effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes AT kimsungrae effectsofpatienttailoredatorvastatintherapyonamelioratingthelevelsofatherogeniclipidsandinflammationbeyondloweringlowdensitylipoproteincholesterolinpatientswithtype2diabetes |